Overhauling the reimbursement system for molecular diagnostics

Nature Biotechnology

Volumn 29, Issue 5, 2011, Pages 390-391

  Malik, Nafees N ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOOD AND DRUG ADMINISTRATION; LETTER; MEDICARE; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REIMBURSEMENT;

BIOLOGICAL MARKERS; HUMANS; INSURANCE, HEALTH; MOLECULAR DIAGNOSTIC TECHNIQUES; POLICY; REIMBURSEMENT MECHANISMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955760748     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1869     Document Type: Letter

References (12)

1. Schulman, K.A. & Tunis, S.R. Nat. Biotechnol. 28, 1157-1159 (2010).
2. Meckley, L.M. & Neumann, P.J. Health Policy 94, 91-100 (2010).
3. Trosman, J.R., Van Bebber, S.L. & Phillips, K.A. J. Oncol. Pract. 6, 238-242 (2010).
4. Anonymous. The New Science of Personalized Medicine: Translating the Promise into Practice (PricewaterhouseCoopers, 2009).
5. Mohr, P.E. & Tunis, S.R. Pharmacoeconomics 28, 153-162 (2010).
6. Tunis, S.R. & Pearson, S.D. Health Aff. 25, 1218-1230 (2006).
7. Atkinson, W. The impact of CED on private payers. Biotechnology Healthcare 24-30 (April 2007).
8. Kaiser Family Foundation. Kaiser Slides: Medicare Enrolment, 1966-2010. (Accessed 26 January 2011).
9. Filmore, D. & Bylander, J. The Gray Sheet (28 June 2010).
10. PricewaterhouseCoopers. Diagnostics 2009: Moving Towards Personalised Medicine (PricewaterhouseCoopers, 2009).
11. The Lewin Group. The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care (The Lewin Group, 2005).
12. Allison, M. Nat. Biotechnol. 26, 509-517 (2008).